Yohei Tabe

Yohei Tabe

Auto-generated profile, based on publicly available information

Yohei Tabe

Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2025 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
YTYohei Tabe
Yohei Tabe
HOHiroaki Ono
Hiroaki Ono
SMSatoshi Matsui
Satoshi Matsui
DADaisuke Asano
Daisuke Asano
YIYoshiya Ishikawa
Yoshiya Ishikawa
DBDaisuke Ban
Daisuke Ban
Background: Systemic therapy is a standard treatment option for pancreatic neuroendocrine neoplasms (Pan-NENs) with unresectable or metastatic disease. Streptozocin (STZ)-based chemotherapy is considered a standard treatment option for tumors with a high Ki-67 index or for cases refractory to molecular targeted agents. More recently, the combination of capecitabine and temozolomide (CAPTEM) therapy has emerged as a new treatment option. Objectives: This study aimed to compare the efficacy, safety, and clinical outcomes between the STZ-based regimen and CAPTEM therapy in patients with unresectable or metastatic Pan-NENs. Design: This was a single-center retrospective study of histologically confirmed Pan-neuroendocrine tumor (NET) patients treated with either STZ-based regimens or CAPTEM between November 2015 and June 2024. Methods: We compared efficacy, safety, and clinical outcomes between the two regimens. Tumor responses were assessed using Response Evaluation Criteria in Solid Tumors version 1.1, and adverse events were graded according to Common Terminology Criteria for Adverse Events version 5.0. The study was conducted in compliance with the STROBE guidelines. Results: Of the 371 patients diagnosed with Pan-NENs, 47 received STZ-based regimen and 21 received CAPTEM therapy. In the NET-G1/G2 patients, the STZ group showed a significantly higher tumor shrinkage rate compared to CAPTEM therapy. Although no significant differences were observed in progression-free survival (PFS) or overall survival between the two groups, subgroup analysis showed that the median PFS in the STZ group was significantly longer than that in the CAPTEM group in NET G1/G2 patients. Renal dysfunction was the main adverse event in the STZ regimen group, while gastrointestinal symptoms were common in the CAPTEM therapy group; however, both were manageable. Conclusion: Both STZ-based regimen and CAPTEM therapy are safe and effective treatment options for advanced Pan-NENs. STZ-based regimen was more beneficial in NET-G1/G2 patients, suggesting Ki-67 index and tumor grade may serve as indicators for treatment selection. Further prospective studies are warranted to validate these findings.

19 August 2026 in Surgical Oncology
Verified
Journal Article
Closed access
YTYohei Tabe
Yohei Tabe
SMSatoshi Matsui
Satoshi Matsui
KOKen Oh
Ken Oh
DADaisuke Asano
Daisuke Asano
YIYoshiya Ishikawa
Yoshiya Ishikawa
DBDaisuke Ban
Daisuke Ban

1 January 2025 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
YTYohei Tabe
Yohei Tabe
DADaisuke Asano
Daisuke Asano
HTHayato Takamizawa
Hayato Takamizawa
SMSatoshi Matsui
Satoshi Matsui
YIYoshiya Ishikawa
Yoshiya Ishikawa
DBDaisuke Ban
Daisuke Ban
INTRODUCTION: While para-aortic lymph node recurrence may occur after curative resection for pancreatic ductal adenocarcinoma (PDAC), it is rarely seen as a late recurrence and is usually treated with systemic chemotherapy. In contrast, recurrence of pancreatic neuroendocrine neoplasms (Pan-NENs) can occur more than a decade after surgery and may be amenable to surgical resection. Although immunohistochemical techniques have significantly enhanced the diagnostic distinction between PDAC and Pan-NEN, challenges remain, particularly in older cases.CASE PRESENTATION: A 77-year-old man underwent distal pancreatectomy for pancreatic body cancer 11 years prior, initially diagnosed as PDAC based on glandular morphology, and received adjuvant S-1 chemotherapy. Surveillance ended after 5 years without recurrence. Eleven years after surgery, imaging performed during evaluation for elevated prostate-specific antigen revealed a 16-mm para-aortic lymph node enlargement. CT-guided biopsy showed neuroendocrine morphology with chromogranin A and synaptophysin positivity, consistent with neuroendocrine tumor (NET). Retrospective histological review of the original surgical specimen revealed previously unrecognized NET-G2 components (Ki-67, 5.0%). Surgical resection of the para-aortic and mesenteric lymph nodes was performed, and pathology confirmed NET-G2 metastases (Ki-67, 6.7%). The patient recovered uneventfully and remains recurrence-free at 7 months postoperatively under active surveillance.CONCLUSIONS: This case highlights the importance of tissue diagnosis when late-onset recurrence is observed in patients with a prior diagnosis of PDAC. It also underscores the potential for extremely delayed recurrence in Pan-NENs and the importance of long-term surveillance. For patients presenting with isolated distant recurrence long after initial treatment for PDAC, biopsy and pathological re-evaluation should be considered to ensure appropriate therapeutic decision-making.

18 July 2026 in Cancer Science
Verified
Journal Article
Open access
PDF file
YTYohei Tabe
Yohei Tabe
ENEito Nakagawa
Eito Nakagawa
DADaisuke Asano
Daisuke Asano
EKEriko Katsuta
Eriko Katsuta
DBDaisuke Ban
Daisuke Ban
SKShogo Kumagai
Shogo Kumagai
Neuroendocrine neoplasms (NENs) are a heterogeneous family of epithelial malignancies that share neuroendocrine differentiation but differ in lineage origin, genomic architecture, immune contexture, and clinical behavior. Pancreatic neuroendocrine neoplasms (PanNENs) are particularly informative because well‐differentiated pancreatic neuroendocrine tumors (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs) arise in the same organ yet follow distinct evolutionary trajectories. Despite advances in surgery, targeted therapy, chemotherapy, and peptide receptor radionuclide therapy (PRRT), advanced PanNENs remain largely incurable, and immune checkpoint blockade has shown limited and inconsistent benefit. Recent genomic, epigenomic, and immune profiling studies indicate that differentiation state and lineage programs are major organizing principles of PanNEN biology. PanNETs are typically defined by chromatin regulatory alterations, relative lineage stability, and weakly inflamed immune microenvironments, although a subset shows increased tumor‐associated macrophage infiltration and other immunoregulatory features linked to aggressive disease. By contrast, PanNECs are characterized by lineage instability, cell‐cycle dysregulation, and a more inflamed yet functionally suppressed immune context, with greater immune‐cell infiltration and more frequent checkpoint pathway engagement. However, these features do not necessarily indicate effective antitumor immunity, because inflammatory engagement may coexist with impaired antigen presentation, including human leukocyte antigen class I loss, tumor‐intrinsic immune evasion, and suppressive myeloid networks. We propose that genomic alterations, epigenetic states, and immune architectures evolve as a coupled system in PanNENs. We discuss how lineage identity shapes antigen presentation defects, immune suppression, and therapeutic vulnerability, and we outline biologically rational, precision‐guided strategies, including epigenetic modulation, targeting of immunosuppressive cell populations, and lineage‐informed therapies.